Viridian Therapeutics, Inc.

Alumis stands to bulk up its financial position as well as its portfolio of drugs to treat immune-mediated diseases through its merger with Acelyrin. But while analysts saw the deal as a positive from

A month after shelving its previous lead drug candidate, izokibep, Acelyrin said on 6 January that it is moving lonigutamab into Phase III in thyroid eye disease with a revised dosing regimen from Pha

Potential competitors to Amgen’s Tepezza (teprotumumab), the only approved drug therapy for thyroid eye disease (TED), keep lining up as privately held Sling Therapeutics unveiled positive Phase IIb/I

Viridian unveiled successful across-the-board Phase III data on 16 December for veligrotug in chronic thyroid eye disease (TED), roughly three months after similar broad Phase III success with the can